Sodium Cromoglicate for Childhood Eczema: Positive Early Scores, a Week-12 Limit and an Open Extension
DOCTOR’S NOTES · ECZEMA EVIDENCE
A childhood eczema trial may sound positive at one visit and inconclusive at another. Sodium cromoglicate research shows why the time point, formulation and analysis group must stay attached to the result. Three related reports should be considered together rather than choosing only the most favorable sentence.
The earlier lotion trial
The 2005 randomized trial assigned 114 children aged 2–12 to a 4% sodium cromoglicate lotion or lotion base for 12 weeks, alongside existing care. Mean SCORAD reductions were 13.2 versus 7.6 points: a 5.6-point difference, 95% confidence interval 1.0–10.3, P=.018. Itch and sleep-loss differences were not significant.
The 208-child emulsion study had a different week-12 conclusion
The 2014 primary abstract reports 104 children per group, aged 2–12, comparing a 4% emulsion with vehicle for 12 weeks. SCORAD differences were significant at week eight, P=.03, but P=.09 at week 12. The latter is not conventionally significant at .05.
| Analysis or report | Important qualification |
|---|---|
| 208-child trial, week eight | A favorable earlier time point. |
| Same trial, week 12 | P=.09 in the reported overall comparison. |
| 127 without major protocol deviations | Week-12 SCORAD P=.04 in a selected analysis set. |
| Different 177-child long-term report | Randomized phase did not show a significant difference. |
Why a selected analysis does not replace the whole comparison
Excluding major protocol deviations can answer whether findings look different among participants who followed the protocol closely. It can also alter the original balance achieved by randomization. The overall and selected analyses should both remain visible; a favorable selected result should not be presented as though it came from every assigned child.
Longer follow-up did not mean longer randomized evidence
The 2015 long-term report enrolled 177 children aged 1–12. Its 12-week randomized phase showed SCORAD reductions of 33% with active emulsion and 39% with vehicle, P=.2331, with no secondary-endpoint differences. Afterward came 12 months of open treatment, completed by 128 children.
A later reduction during open treatment does not turn the negative controlled phase into a positive long-term comparison. Once treatment is known and there is no continuing vehicle control, improvement can describe the course of observed participants but cannot isolate the added effect with the original randomized protection.
What parents can ask
Ask whether a proposed preparation matches the tested skin formulation, which result supports the recommendation and how progress will be measured. A medicine with the same name in an oral, nasal or eye preparation is not interchangeable with a studied cutaneous lotion. Do not apply another formulation to a child’s skin on the basis of these papers.
For school and activity schedules, the useful care plan includes instructions for application, unwanted effects and reassessment. AAD guidance provides the broader clinical reference. These mixed historical results should not be simplified into a universal steroid-replacement promise.
How an add-on trial can improve within groups without establishing added benefit
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.